AU2006284490A1 - Compositions and methods to control angiogenesis with cupredoxins - Google Patents

Compositions and methods to control angiogenesis with cupredoxins Download PDF

Info

Publication number
AU2006284490A1
AU2006284490A1 AU2006284490A AU2006284490A AU2006284490A1 AU 2006284490 A1 AU2006284490 A1 AU 2006284490A1 AU 2006284490 A AU2006284490 A AU 2006284490A AU 2006284490 A AU2006284490 A AU 2006284490A AU 2006284490 A1 AU2006284490 A1 AU 2006284490A1
Authority
AU
Australia
Prior art keywords
cupredoxin
peptide
cells
residues
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006284490A
Other languages
English (en)
Other versions
AU2006284490A8 (en
Inventor
Craig Beattie
Ananda Chakrabarty
Tapas Das Gupta
Rajeshwari Mehta
Brad Taylor
Tohru Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois at Urbana-Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Priority claimed from US11/436,592 external-priority patent/US7381701B2/en
Application filed by University of Illinois at Urbana-Champaign, University of Illinois System filed Critical University of Illinois at Urbana-Champaign
Publication of AU2006284490A1 publication Critical patent/AU2006284490A1/en
Publication of AU2006284490A8 publication Critical patent/AU2006284490A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2006284490A 2005-07-19 2006-07-19 Compositions and methods to control angiogenesis with cupredoxins Abandoned AU2006284490A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US70029705P 2005-07-19 2005-07-19
US60/700,297 2005-07-19
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US11/244,105 2005-10-06
US76474906P 2006-02-03 2006-02-03
US60/764,749 2006-02-03
US11/436,592 2006-05-19
US11/436,592 US7381701B2 (en) 2001-02-15 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
PCT/US2006/027940 WO2007024368A2 (en) 2005-07-19 2006-07-19 Compositions and methods to control angiogenesis with cupredoxins

Publications (2)

Publication Number Publication Date
AU2006284490A1 true AU2006284490A1 (en) 2007-03-01
AU2006284490A8 AU2006284490A8 (en) 2008-02-28

Family

ID=37772089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006284490A Abandoned AU2006284490A1 (en) 2005-07-19 2006-07-19 Compositions and methods to control angiogenesis with cupredoxins

Country Status (10)

Country Link
EP (1) EP1904081A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009502797A (cg-RX-API-DMAC7.html)
KR (1) KR20080034905A (cg-RX-API-DMAC7.html)
AU (1) AU2006284490A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0615555A2 (cg-RX-API-DMAC7.html)
CA (1) CA2615560A1 (cg-RX-API-DMAC7.html)
IL (1) IL188691A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008000993A (cg-RX-API-DMAC7.html)
NO (1) NO20080829L (cg-RX-API-DMAC7.html)
WO (1) WO2007024368A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158574B2 (en) * 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
EP2061498A4 (en) * 2006-09-14 2009-11-04 Univ Illinois COMPOSITIONS AND METHOD FOR CANCER PREPARATION WITH CUPREDOXINES
AU2007329375A1 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
UA97466C2 (ru) * 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
AU2006277009A1 (en) * 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
JP2008545398A (ja) * 2005-05-20 2008-12-18 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ キュプレドキシンおよびシトクロムcを用いてhiv感染を治療するための組成物および方法
AU2006251742A1 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome

Also Published As

Publication number Publication date
WO2007024368A3 (en) 2007-10-11
WO2007024368A2 (en) 2007-03-01
IL188691A0 (en) 2008-08-07
AU2006284490A8 (en) 2008-02-28
KR20080034905A (ko) 2008-04-22
NO20080829L (no) 2008-04-02
EP1904081A4 (en) 2008-12-03
EP1904081A2 (en) 2008-04-02
CA2615560A1 (en) 2007-03-01
BRPI0615555A2 (pt) 2009-07-14
MX2008000993A (es) 2008-03-19
JP2009502797A (ja) 2009-01-29

Similar Documents

Publication Publication Date Title
US9107881B2 (en) Compositions and methods to control angiogenesis with cupredoxins
US8623816B2 (en) Compositions and methods for treating malaria with cupredoxin and cytochrome
US8232244B2 (en) Compositions and methods to prevent cancer with cupredoxins
US10889621B2 (en) Compositions and methods for treating conditions related to ephrin signaling with Cupredoxins
CA2582164A1 (en) Cupredoxin derived transport agents and methods of use thereof
EP1653990A1 (en) Use of polypeptides of the cupredoxin family in cancer therapy
SG174784A1 (en) Compositions and methods to prevent cancer with cupredoxins
CA2608512A1 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US20080221015A1 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
CA2615560A1 (en) Compositions and methods to control angiogenesis with cupredoxins
AU2010201360A1 (en) Compositions and methods for treating malaria with cupredoxin and cytochrome
CN101272800A (zh) 使用铜氧还蛋白控制血管发生的组合物和方法
ZA200602126B (en) Use of polypeptides of the cupredoxin family in cancer therapy

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 22, NO 6, PAGE(S) 671 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, APPLICATION NO. 2006284490, UNDER INID (71) CORRECT THE NAME TO READ THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application